Genprex, Inc.   Report issue

For profit Phase 2
Founded: Austin TX United States (2009)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2014
NCT01455389
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Genprex, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 9